These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist. Palucki BL; Park MK; Nargund RP; Ye Z; Sebhat IK; Pollard PG; Kalyani RN; Tang R; Macneil T; Weinberg DH; Vongs A; Rosenblum CI; Doss GA; Miller RR; Stearns RA; Peng Q; Tamvakopoulos C; McGowan E; Martin WJ; Metzger JM; Shepherd CA; Strack AM; Macintyre DE; Van der Ploeg LH; Patchett AA Bioorg Med Chem Lett; 2005 Jan; 15(1):171-5. PubMed ID: 15582434 [TBL] [Abstract][Full Text] [Related]
5. Discovery of potent, selective, and orally bioavailable 3H-spiro[isobenzofuran-1,4'-piperidine] based melanocortin subtype-4 receptor agonists. Guo L; Ye Z; Liu J; He S; Bakshi RK; Sebhat IK; Dobbelaar PH; Hong Q; Jian T; Dellureficio JP; Tsou NN; Ball RG; Weinberg DH; MacNeil T; Tang R; Tamvakopoulos C; Peng Q; Chen HY; Chen AS; Martin WJ; MacIntyre DE; Strack AM; Fong TM; Wyvratt MJ; Nargund RP Bioorg Med Chem Lett; 2010 Aug; 20(16):4895-900. PubMed ID: 20621473 [TBL] [Abstract][Full Text] [Related]
6. Optimization of privileged structures for selective and potent melanocortin subtype-4 receptor ligands. Hong Q; Bakshi RK; Dellureficio J; He S; Ye Z; Dobbelaar PH; Sebhat IK; Guo L; Liu J; Jian T; Tang R; Kalyani RN; Macneil T; Vongs A; Rosenblum CI; Weinberg DH; Peng Q; Tamvakopoulos C; Miller RR; Stearns RA; Cashen D; Martin WJ; Chen AS; Metzger JM; Chen HY; Strack AM; Fong TM; Maclntyre E; Van der Ploeg LH; Wyvratt MJ; Nargund RP Bioorg Med Chem Lett; 2010 Aug; 20(15):4483-6. PubMed ID: 20598533 [TBL] [Abstract][Full Text] [Related]
7. Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia. Chen C; Jiang W; Tucci F; Tran JA; Fleck BA; Hoare SR; Joppa M; Markison S; Wen J; Sai Y; Johns M; Madan A; Chen T; Chen CW; Marinkovic D; Arellano M; Saunders J; Foster AC J Med Chem; 2007 Nov; 50(22):5249-52. PubMed ID: 17918824 [TBL] [Abstract][Full Text] [Related]
8. Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2-azabicyclo[2.2.2]octane-6-carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist. Ye Z; Guo L; Barakat KJ; Pollard PG; Palucki BL; Sebhat IK; Bakshi RK; Tang R; Kalyani RN; Vongs A; Chen AS; Chen HY; Rosenblum CI; MacNeil T; Weinberg DH; Peng Q; Tamvakopoulos C; Miller RR; Stearns RA; Cashen DE; Martin WJ; Metzger JM; Strack AM; MacIntyre DE; Van der Ploeg LH; Patchett AA; Wyvratt MJ; Nargund RP Bioorg Med Chem Lett; 2005 Aug; 15(15):3501-5. PubMed ID: 15982875 [TBL] [Abstract][Full Text] [Related]
9. 2-Piperazinecarboxamides as potent and selective melanocortin subtype-4 receptor agonists. Palucki BL; Park MK; Nargund RP; Tang R; MacNeil T; Weinberg DH; Vongs A; Rosenblum CI; Doss GA; Miller RR; Stearns RA; Peng Q; Tamvakopoulos C; Van der Ploeg LH; Patchett AA Bioorg Med Chem Lett; 2005 Apr; 15(8):1993-6. PubMed ID: 15808454 [TBL] [Abstract][Full Text] [Related]
10. Discovery of highly potent and efficacious MC4R agonists with spiroindane N-Me-1,2,4-triazole privileged structures for the treatment of obesity. He S; Ye Z; Dobbelaar PH; Bakshi RK; Hong Q; Dellureficio JP; Sebhat IK; Guo L; Liu J; Jian T; Lai Y; Franklin CL; Reibarkh M; Holmes MA; Weinberg DH; MacNeil T; Tang R; Tamvakopoulos C; Peng Q; Miller RR; Stearns RA; Chen HY; Chen AS; Strack AM; Fong TM; Wyvratt MJ; Nargund RP Bioorg Med Chem Lett; 2010 Nov; 20(22):6524-32. PubMed ID: 20933410 [TBL] [Abstract][Full Text] [Related]
11. Potent and orally active non-peptide antagonists of the human melanocortin-4 receptor based on a series of trans-2-disubstituted cyclohexylpiperazines. Tucci FC; White NS; Markison S; Joppa M; Tran JA; Fleck BA; Madan A; Dyck BP; Parker J; Pontillo J; Arellano LM; Marinkovic D; Jiang W; Chen CW; Gogas KR; Goodfellow VS; Saunders J; Foster AC; Chen C Bioorg Med Chem Lett; 2005 Oct; 15(19):4389-95. PubMed ID: 16098742 [TBL] [Abstract][Full Text] [Related]
13. Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamides. Fotsch C; Han N; Arasasingham P; Bo Y; Carmouche M; Chen N; Davis J; Goldberg MH; Hale C; Hsieh FY; Kelly MG; Liu Q; Norman MH; Smith DM; Stec M; Tamayo N; Xi N; Xu S; Bannon AW; Baumgartner JW Bioorg Med Chem Lett; 2005 Mar; 15(6):1623-7. PubMed ID: 15745810 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure-activity relationships of novel arylpiperazines as potent and selective agonists of the melanocortin subtype-4 receptor. Richardson TI; Ornstein PL; Briner K; Fisher MJ; Backer RT; Biggers CK; Clay MP; Emmerson PJ; Hertel LW; Hsiung HM; Husain S; Kahl SD; Lee JA; Lindstrom TD; Martinelli MJ; Mayer JP; Mullaney JT; O'Brien TP; Pawlak JM; Revell KD; Shah J; Zgombick JM; Herr RJ; Melekhov A; Sampson PB; King CH J Med Chem; 2004 Jan; 47(3):744-55. PubMed ID: 14736255 [TBL] [Abstract][Full Text] [Related]
15. Discovery of a selective small-molecule melanocortin-4 receptor agonist with efficacy in a pilot study of sexual dysfunction in humans. Lansdell MI; Hepworth D; Calabrese A; Brown AD; Blagg J; Burring DJ; Wilson P; Fradet D; Brown TB; Quinton F; Mistry N; Tang K; Mount N; Stacey P; Edmunds N; Adams C; Gaboardi S; Neal-Morgan S; Wayman C; Cole S; Phipps J; Lewis M; Verrier H; Gillon V; Feeder N; Heatherington A; Sultana S; Haughie S; Martin SW; Sudworth M; Tweedy S J Med Chem; 2010 Apr; 53(8):3183-97. PubMed ID: 20329799 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and SAR of potent and orally bioavailable tert-butylpyrrolidine archetype derived melanocortin subtype-4 receptor modulators. Guo L; Ye Z; Ujjainwalla F; Sings HL; Sebhat IK; Huber J; Weinberg DH; Tang R; MacNeil T; Tamvakopoulos C; Peng Q; MacIntyre E; van der Ploeg LH; Goulet MT; Wyvratt MJ; Nargund RP Bioorg Med Chem Lett; 2008 Jun; 18(11):3242-7. PubMed ID: 18479920 [TBL] [Abstract][Full Text] [Related]
17. Spiroindane based amides as potent and selective MC4R agonists for the treatment of obesity. He S; Ye Z; Dobbelaar PH; Sebhat IK; Guo L; Liu J; Jian T; Lai Y; Franklin CL; Bakshi RK; Dellureficio JP; Hong Q; Weinberg DH; Macneil T; Tang R; Strack AM; Tamvakopoulos C; Peng Q; Miller RR; Stearns RA; Chen HY; Chen AS; Fong TM; Wyvratt MJ; Nargund RP Bioorg Med Chem Lett; 2010 Aug; 20(15):4399-405. PubMed ID: 20598882 [TBL] [Abstract][Full Text] [Related]
18. Piperazine imidazo[1,5-a]quinoxaline ureas as high-affinity GABAA ligands of dual functionality. Jacobsen EJ; Stelzer LS; TenBrink RE; Belonga KL; Carter DB; Im HK; Im WB; Sethy VH; Tang AH; VonVoigtlander PF; Petke JD; Zhong WZ; Mickelson JW J Med Chem; 1999 Apr; 42(7):1123-44. PubMed ID: 10197957 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists. Chen C; Tucci FC; Jiang W; Tran JA; Fleck BA; Hoare SR; Wen J; Chen T; Johns M; Markison S; Foster AC; Marinkovic D; Chen CW; Arellano M; Harman J; Saunders J; Bozigian H; Marks D Bioorg Med Chem; 2008 May; 16(10):5606-18. PubMed ID: 18417348 [TBL] [Abstract][Full Text] [Related]